AAAAAA

   
Results: 1-11 |
Results: 11
Enhanced apoptotic activity of a p53 variant in tumors resistant to wild-type p53 treatment
Authors: Atencio, IA Avanzini, JB Johnson, D Neuteboom, S Vaillancourt, MT Nielsen, LL Hajian, G Sutjipto, S Sugarman, BJ Philopena, J McAllister, DL Beltran, JC Nodelman, M Ramachandra, M Wills, KN
Citation: Ia. Atencio et al., Enhanced apoptotic activity of a p53 variant in tumors resistant to wild-type p53 treatment, MOL THER, 4(1), 2001, pp. 5-12
Orally bioavailable farnesyltransferase inhibitors as anticancer agents intransgenic and xenograft models
Authors: Liu, M Bishop, WR Nielsen, LL Bryant, MS Kirschmeier, P
Citation: M. Liu et al., Orally bioavailable farnesyltransferase inhibitors as anticancer agents intransgenic and xenograft models, METH ENZYM, 333, 2001, pp. 306-318
Efficient assembly of recombinant major histocompatibility complex class Imolecules with preformed disulfide bonds
Authors: Pedersen, LO Nissen, MH Hansen, NJV Nielsen, LL Lauenmoller, SL Blicher, T Nansen, A Sylvester-Hvid, C Thromsen, AR Buus, S
Citation: Lo. Pedersen et al., Efficient assembly of recombinant major histocompatibility complex class Imolecules with preformed disulfide bonds, EUR J IMMUN, 31(10), 2001, pp. 2986-2996
Combination therapy with SCH58500 (p53 adenovirus) and cyclophosphamide inpreclinical cancer models
Authors: Nielsen, LL
Citation: Ll. Nielsen, Combination therapy with SCH58500 (p53 adenovirus) and cyclophosphamide inpreclinical cancer models, ONCOL REP, 7(6), 2000, pp. 1191-1196
NK cells mediate the anti-tumor effects of E1-deleted, type 5 adenovirus in a human tumor xenograft model
Authors: Nielsen, LL
Citation: Ll. Nielsen, NK cells mediate the anti-tumor effects of E1-deleted, type 5 adenovirus in a human tumor xenograft model, ONCOL REP, 7(1), 2000, pp. 151-155
Development and validation of sensitive assays to quantitate gene expression after p53 gene therapy and paclitaxel chemotherapy using in vivo dosing in tumor xenograft models
Authors: Wen, SF Xie, L McDonald, M DiGiacomo, R Chang, A Gurnani, M Shi, B Liu, SX Indelicato, SR Hutchins, B Nielsen, LL
Citation: Sf. Wen et al., Development and validation of sensitive assays to quantitate gene expression after p53 gene therapy and paclitaxel chemotherapy using in vivo dosing in tumor xenograft models, CANC GENE T, 7(11), 2000, pp. 1469-1480
The farnesyl protein transferase inhibitor SCH66336 synergizes with taxanes in vitro and enhances their antitumor activity in vivo
Authors: Shi, B Yaremko, B Hajian, G Terracina, G Bishop, WR Liu, M Nielsen, LL
Citation: B. Shi et al., The farnesyl protein transferase inhibitor SCH66336 synergizes with taxanes in vitro and enhances their antitumor activity in vivo, CANC CHEMOT, 46(5), 2000, pp. 387-393
Derivation and initial characterization of a mouse mammary tumor cell linecarrying the polyomavirus middle T antigen: Utility in the development of novel cancer therapeutics
Authors: Nielsen, LL Gurnani, M Shi, B Terracina, G Johnson, RC Carroll, J Mathis, JM Hajian, G
Citation: Ll. Nielsen et al., Derivation and initial characterization of a mouse mammary tumor cell linecarrying the polyomavirus middle T antigen: Utility in the development of novel cancer therapeutics, CANCER RES, 60(24), 2000, pp. 7066-7074
Adenovirus mediated p53 gene therapy has greater efficacy when combined with chemotherapy against human head and neck, ovarian, prostate, and breast cancer
Authors: Gurnani, M Lipari, P Dell, J Shi, B Nielsen, LL
Citation: M. Gurnani et al., Adenovirus mediated p53 gene therapy has greater efficacy when combined with chemotherapy against human head and neck, ovarian, prostate, and breast cancer, CANC CHEMOT, 44(2), 1999, pp. 143-151
Combination therapy with the farnesyl protein transferase inhibitor SCH66336 and SCH58500 (p53 adenovirus) in preclinical cancer models
Authors: Nielsen, LL Shi, B Hajian, G Yaremko, B Lipari, P Ferrari, E Gurnani, M Malkowski, M Chen, JP Bishop, WR Liu, M
Citation: Ll. Nielsen et al., Combination therapy with the farnesyl protein transferase inhibitor SCH66336 and SCH58500 (p53 adenovirus) in preclinical cancer models, CANCER RES, 59(23), 1999, pp. 5896-5901
The use of laser scanning cytometry to assess depth of penetration of adenovirus p53 gene therapy in human xenograft biopsies
Authors: Grace, MJ Xie, L Musco, ML Cui, S Gurnani, M DiGiacomo, R Chang, A Indelicato, S Syed, J Johnson, R Nielsen, LL
Citation: Mj. Grace et al., The use of laser scanning cytometry to assess depth of penetration of adenovirus p53 gene therapy in human xenograft biopsies, AM J PATH, 155(6), 1999, pp. 1869-1878
Risultati: 1-11 |